Email This

A 55-Year-Old Man in Chronic-Phase Chronic Myelogenous Leukemia With Suboptimal Response to Imatinib Mesylate CME

Jorge Cortes, MD Author Information and Disclosures

Release Date: January 31, 2008; Valid for credit through January 31, 2009

Credits Available

Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians
Estimated Completion Time: 45 minutes

To participate in this activity: 1) review the target audience, learning objectives and author disclosures, 2) study the education content 3) answer the posttest and evaluation 4) view/print certificate View details

Contents of This CME Activity

A 55-Year-Old Man in Chronic-Phase Chronic Myelogenous Leukemia With Suboptimal Response to Imatinib MesylateJorge Cortes, MD

Go to CME Test Questions

Legal Disclaimer

The materials presented here were not produced by eMedicine and do not necessarily reflect the views of eMedicine or companies that support educational programming on www.emedicine.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in this educational activity.

Provided by education | outcomes | science

Learning Objectives

After completing this case, participants should be better able to:

Describe how dose optimization and novel agents can best be integrated into the treatment strategy for patients with chronic myelogenous leukemia (CML);
Appropriately manage adverse events in patients undergoing treatment for CML;
Discuss the results of clinical trials evaluating pharmacologic treatments for CML.

Author Disclosures

Jorge Cortes, MD
Sources of Funding for Research: BMS, ChemGenex, Merck, Novartis Inc., Wyeth, The Vaccine Company
Consulting Agreements: Speaker's Bureau/Honorarium Agreements: Novartis, Breakthrough Therapeutics.

education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider